Venker Eric sold 200,000 shares of Roivant Sciences Ltd. at $36.62 for −$7.32M on Sep 30, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
President & Immunovant CEO
President & Immunovant CEO
Filed Oct 2, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$7,324,000Shares × reported price
Shares traded
200,000Common Shares
Price per share
$36.62Reported price. Read footnotes for ranges.
% of reported position traded
11.12%This security and ownership context
Holdings after
1,599,154Direct
Trade date
Sep 30, 2026Sell
Filed
Oct 2, 2026, 5:37 PM ET2-day reporting delay
Accession
0001635088-26-000108Code S · Transaction 235541
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 1,799,154 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 30, 2026Option exercise200,000$3.85$770,000Trade 235540
Sep 30, 2026Option exercise200,000$0.00$0Trade 235542
3 transaction rows in this filing. Joint filers share the same rows.

ROIV price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ROIV · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −3%1w ago +3.1%1d ago +2.2%
Returns since7d −0.8%30d +3.3%90d180d1y

Footnotes in full

F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.49 to $36.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025. F2: Reflects an award of stock options to purchase Common Shares that is fully vested.